Acadia Pharma (ACAD) Misses Q4 EPS by 3c

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $130.76 million versus the consensus estimate of $135.6 million.

GUIANCE:

2022 Financial Guidance

• NUPLAZID net sales guidance in Parkinson’s disease psychosis is $510 to $560 million.
• GAAP R&D guidance is $355 to $375 million and includes approximately $25 million of stock-based compensation expense.
• GAAP SG&A guidance is $360 to $380 million and includes approximately $45 million of stock-based compensation expense.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance